Tyrosine kinase inhibitors for chronic myeloid leukemia are associated with cardiovascular, metabolic, and pulmonary toxicities requiring preemptive assessment and prompt management to improve outcomes.
What are the cardiovascular, metabolic, and pulmonary toxicities associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia, and how should they be managed?
This review highlights the importance of preemptive assessment and management of cardiovascular, metabolic, and pulmonary toxicities in CML patients treated with TKIs to minimize complications.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, the incidence of which increases with age. Tyrosine kinase inhibitors (TKIs) are the mainstay of CML treatment, including imatinib, nilotinib, dasatinib, bosutinib, and ponatinib. Beyond matching patient disease profiles with TKI specificity, differences in the efficacy and toxicity profiles and a patient's comorbid risk factors should be considered when selecting the most appropriate agent. Our objectives are to review the incidence and severity of cardiovascular, metabolic, and pulmonary disorders associated with these TKIs, highlighting differences in adverse event profiles, suggested risk-mitigation strategies, and guidance for TKI selection in different settings. Patients receiving TKI agents for CML should be monitored for signs and symptoms of toxicity throughout therapy. Preemptive assessment, early toxicity recognition, and prompt management of cardiovascular, metabolic, and pulmonary toxicities can minimize treatment-limiting complications and improve outcomes in patients with CML.
Medeiros et al. (Sat,) conducted a review in Chronic myeloid leukemia. Tyrosine kinase inhibitors was evaluated. Tyrosine kinase inhibitors for chronic myeloid leukemia are associated with cardiovascular, metabolic, and pulmonary toxicities requiring preemptive assessment and prompt management to improve outcomes.